Hosted on MSN1h
Yeovil MP warns of 'growing health crisis' after liver event
Yeovil MP Adam Dance warned of a "growing health crisis" after attending the British Liver Trust's Parliamentary event on ...
El País in English4h
Ramón Bataller, hepatologist: ‘The combination of alcohol and cocaine is explosive and many young people are paying for it’
The researcher, a global liver damage expert, sounds the alarm over our limited awareness of the connection between drug ...
Daily5h
Lactate Dehydrogenase Levels Predict Severity of MAFLD and Metabolic Syndrome: Study Finds
"Patients with metabolic-associated steatohepatitis (MASH) also showed higher LDH levels. LDH levels were positively linked ...
Founder of pH Miracle Diet found guilty of elder abuse and treating patients without a license
Robert Young, author of the pH Miracle Diet found guilty of treating terminally ill patients without medical credentials.
The Punch Newspapers8h
Understanding gallbladder issues in sickle cell patients
High bilirubin levels increase the risk of developing bilirubin gallstones—a type of gallstone more prevalent in Sickle Cell ...
WBBJ-TV18h
Former athlete shares her experience with rare liver disease
Rare Disease Day is February 28. Primary sclerosing cholangitis or PSC is a rare liver disease characterized by progressive ...
Delcath Systems: Strong Position In Metastatic Uveal Melanoma, But Broader Growth Challenges Ahead
Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.
Malaysian Reserve21h
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
GENFIT S.A.: GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...
Medscape23h
Considerations for Prescribing GLP-1s Get More Complicated
New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.